Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Here is a quick snapshot of where each medication stands: Tirzepatide (brand names: Mounjaro for diabetes, Zepbound for weight loss): Greater average weight loss in trials, dual receptor mechanism, no FDA-approved cardiovascular outcomes indication as of 2026 Semaglutide (brand names: Ozempic for diabetes, Wegovy for weight loss): Slightly lower average weight loss, single receptor mechanism, FDA-approved for reducing major cardiovascular events in patients with established heart disease Administration: Both are once-weekly injections
PlexusDx has no commercial relationship with Eden, with the maker of Ozempic, or with any brand referenced here, and publishes no affiliate links
Protein-forward, whole-food diets with a modest caloric deficit, combined with resistance training and adequate sleep, drive the same lipolysis pathways that AOD-9604 targets pharmacologically
Neither reflects well on their quality control practices
Weight loss is almost never quick or easy, especially with conditions like obesity and diabetes
Gilca-Blanariu, G.-E., Trifan, A., Ciocoiu, M., Popa, I
